Literature DB >> 24673285

High-frequency p16(INK) (4A) promoter methylation is associated with histone methyltransferase SETDB1 expression in sporadic cutaneous melanoma.

Maria Kostaki1, Argyro D Manona, Irene Stavraka, Penelope Korkolopoulou, Georgia Levidou, Eleni-Andriana Trigka, Eleftheria Christofidou, Grigorios Champsas, Alexandros J Stratigos, Andreas Katsambas, Othon Papadopoulos, Christina Piperi, Athanasios G Papavassiliou.   

Abstract

Epigenetic mechanisms participate in melanoma development and progression. The effect of histone modifications and their catalysing enzymes over euchromatic promoter DNA methylation in melanoma remains unclear. This study investigated the potential association of p16(INK) (4A) promoter methylation with histone methyltransferase SETDB1 expression in Greek patients with sporadic melanoma and their correlation with clinicopathological characteristics. Promoter methylation was detected by methylation-specific PCR in 100 peripheral blood samples and 58 melanoma tissues from the same patients. Cell proliferation (Ki-67 index), p16(INK) (4A) and SETDB1 expression were evaluated by immunohistochemistry. High-frequency promoter methylation (25.86%) was observed in tissue samples and correlated with increased cell proliferation (P = 0.0514). p16(INK) (4A) promoter methylation was higher in vertical growth-phase (60%) melanomas than in radial (40%, P = 0.063) and those displaying epidermal involvement (P = 0.046). Importantly, p16(INK) (4A) methylation correlated with increased melanoma thickness according to Breslow index (P = 0.0495) and marginally with increased Clark level (I/II vs III/IV/V, P = 0.070). Low (1-30%) p16(INK) (4A) expression was detected at the majority (19 of 54) of melanoma cases (35.19%), being marginally correlated with tumor lymphocytic infiltration (P = 0.078). SETDB1 nuclear immunoreactivity was observed in 47 of 57 (82.46%) cases, whereas 27 of 57 (47.37%) showed cytoplasmic immunoexpression. Cytoplasmic SETDB1 expression correlated with higher frequency of p16(INK) (4A) methylation and p16(INK) (4A) expression (P = 0.033, P = 0.011, respectively). Increased nuclear SETDB1 levels were associated with higher mitotic count (0-5/mm(2) vs >5/mm(2) , P = 0.0869), advanced Clark level (III-V, P = 0.0380), epidermal involvement (P = 0.0331) and the non-chronic sun exposure-associated melanoma type (P = 0.0664). Our data demonstrate for the first time the association of histone methyltransferase SETDB1 with frequent methylation of the euchromatic p16(INK) (4A) promoter and several prognostic parameters in melanomas.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Breslow index; Clark level; SETDB1; mitotic count; p16INK4A; promoter methylation; vertical growth

Mesh:

Substances:

Year:  2014        PMID: 24673285     DOI: 10.1111/exd.12398

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  16 in total

Review 1.  Epigenetic markers in melanoma.

Authors:  Weimin Guo; Ting Xu; Jonathan J Lee; George F Murphy; Christine G Lian
Journal:  Melanoma Manag       Date:  2015-11-24

2.  Solar-simulated ultraviolet radiation induces histone 3 methylation changes in the gene promoters of matrix metalloproteinases 1 and 3 in primary human dermal fibroblasts.

Authors:  Lisa Gesumaria; Mary S Matsui; Thomas Kluz; Max Costa
Journal:  Exp Dermatol       Date:  2015-03-09       Impact factor: 3.960

Review 3.  The Wnts of change: How Wnts regulate phenotype switching in melanoma.

Authors:  Marie R Webster; Curtis H Kugel; Ashani T Weeraratna
Journal:  Biochim Biophys Acta       Date:  2015-11-04

Review 4.  Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression.

Authors:  Nirmalya Saha; Andrew G Muntean
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-26       Impact factor: 10.680

5.  Epigenetic effects of cadmium in cancer: focus on melanoma.

Authors:  Mario Venza; Maria Visalli; Carmelo Biondo; Rosaria Oteri; Federica Agliano; Silvia Morabito; Gerardo Caruso; Maria Caffo; Diana Teti; Isabella Venza
Journal:  Curr Genomics       Date:  2014-12       Impact factor: 2.236

Review 6.  Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming.

Authors:  Joachim Torrano; Abdullah Al Emran; Heinz Hammerlindl; Helmut Schaider
Journal:  Clin Epigenetics       Date:  2019-03-08       Impact factor: 6.551

7.  Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients.

Authors:  Aikaterini F Giannopoulou; Eumorphia G Konstantakou; Athanassios D Velentzas; Socratis N Avgeris; Margaritis Avgeris; Nikos C Papandreou; Ilianna Zoi; Vicky Filippa; Stamatia Katarachia; Antonis D Lampidonis; Anastasia Prombona; Popi Syntichaki; Christina Piperi; Efthimia K Basdra; Vassiliki Iconomidou; Evangelia Papadavid; Ema Anastasiadou; Issidora S Papassideri; Athanasios G Papavassiliou; Gerassimos E Voutsinas; Andreas Scorilas; Dimitrios J Stravopodis
Journal:  Int J Mol Sci       Date:  2019-02-21       Impact factor: 5.923

8.  Knockdown of SET Domain, Bifurcated 1 suppresses head and neck cancer cell viability and wound-healing ability in vitro.

Authors:  Sibel Özdaş
Journal:  Turk J Biol       Date:  2019-10-14

Review 9.  Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer.

Authors:  Ran Zhao; Bu Young Choi; Mee-Hyun Lee; Ann M Bode; Zigang Dong
Journal:  EBioMedicine       Date:  2016-05-03       Impact factor: 8.143

10.  Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation.

Authors:  Milu Wu; Baohua Fan; Qijing Guo; Yan Li; Rong Chen; Nannan Lv; Yinzhuo Diao; Yushuang Luo
Journal:  Biol Res       Date:  2018-10-11       Impact factor: 5.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.